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Summary 
Transfer of human chromosome 11, which contains 
the myoD locus, from primary fibrobiasts into 10TM 
ceils results in activation of myoD. in contrast, hybrids 
that retain human chromosome 11 and additional hu- 
man chromosomes fail to activate myoD. We show that 
human chromosome 4 Inhibits myoD activation. myoD 
enhancer/promoter reporter constructs show that re- 
pression is at the transcriptional level. Chromosome 
fragment-containing hybrids localize the repressing 
activity to the region of 4p that contains the homeobox 
gene MSX7. MSXl is expressed in primary human fl- 
brobiasts and in lOT% ceils containing human chro- 
mosome 4, while parental 10TM ceils do not express 
Msxl . Forced expression of Msxl represses myoD en- 
hancer activity. Msxl protein binds to the myoD en- 
hancer and likely represses myoD transcription di- 
rectly. Antisense MSXl relieves repression mediated 
by chromosome 4. We conclude that MSXl inhibits 
transcription of myoD and that myoD Is a target for 
homeobox gene regulation. 
introduction 
Taylor and Jones (1979) showed that incorporation of 
5-azacytidine @a-C) into the DNA of the mouse embry- 
onic fibroblast cell line C3HlOTV2 (lOT%) can generate 
colonies capable of forming muscle, fat, and cartilage. 
Demethyiation and subsequent expression of specific loci 
involved in determining each cell type is thought to be 
involved in the conversion process (Jones and Taylor, 
1980). The frequency of myogenic conversion (as high 
as 50%) after treatment with aza-C is consistent with the 
activation of a small number of genes and possibly a single 
gene (Konieczny and Emerson, 1984). Genomic DNA 
transfection experiments indicate that myoblast DNA, but 
not lOTV!2 DNA, converts lOTV2 cells into stably deter- 
mined myoblasts at frequencies consistent with transfer 
of a single genetic locus (Lassar et al., 1988). Myogenic 
conversion of 1 OTV2 cells by transfection of myoblast DNA 
but not lOTV2 DNA supports the hypothesis that a myo- 
genie determination gene that is inactive in lOTV2 ceils 
becomes structurally modified following treatment with 
aza-C. The genomic transfection experiments also sug- 
gest that lOTV2 ceils do not express Vans-acting factors 
that can repress the transferred myogenic determination 
gene. Although it seems likely that the myoD gene is the 
relevant target of aza-C (lhayer and Weintraub, 1990), it 
is not known which genes are directly activated by aza-C. 
One mechanism controlling activation of myoD during 
development may be removal or inactivation of negative 
control. This notion comes from experiments that demon- 
strated that myoD is subject to trans-negative regulation 
in primary nonmuscle tissue (Thayer and Weintraub, 
1990). We showed that transfer of human chromosome 11, 
containing the human myoD locus, from primary dipioid 
fibrobiasts into lOTV2 ceils results in activation of the hu- 
man myoD gene and myogenic conversion. in contrast, 
data obtained from whoieceli hybrids indicates that pri- 
mary fibrobiasts contain an activity capable of inhibiting 
myoD activation. Thus, while transfer of human chromo- 
some 11 into 1 OTV’2 cells activates myogenesis, transfer 
of additional human chromosomes along with chromo- 
some 11 prevents myogenesis. Detailed karyotypic anaiy- 
sis of existing hybrids suggest that human chromosomes 
4 and 8 are involved in inhibiting activation of myoD 
(Thayer and Weintraub, 1990). 
We show that chromosome 4, but not 8, inhibits myoD 
activation in lOTV2 cells. Chromosome fragment-con- 
taining hybrids localize the inhibitory locus to the short arm 
of chromosome 4, in the region containing the homeobox 
gene MSXl. An examination of early limb development in 
the mouse reveals a pattern of Msxl expression consistent 
with a role as 3 negative regulator of myogenesis. We 
show that Msxl inhibits expression of myoD at the tran- 
scriptional level and that this inhibition is likely due to djrect 
interaction with the myoD enhancer. Furthermore, trans- 
fection of chromosome 4 containing lOT% cells with an 
MSX7 antisense expression vector results in levels of 
myoD enhancer activity equal to that found in 1 OTV2 ceils. 
Therefore, we conclude that human MSXl inhibits activa- 
tion of myoD expression in primary fibroblast x 1 OTV2 cell 
hybrids. 
Results 
inhibition of myoD Expression In lOT% Ceils 
by Human Fibrobiast Chromosome 4 
To dissect the role of chromosomes 4 and 8 on inhibition 
of myoD expression, we transferred each chromosome, 
containing neb vector insertions, individually into 1 OT1/2 
cells. These microcell fusions generated the lOTV2(4n) 
Cdl 
612 
and lOT1/2(8n) microcell hybrids, containing human fibro- 
blast chromosomes 4 and 8, respectively. Because micro- 
cell fusion often generates hybrids that contain chromo- 
some fragments (Leach et al., 1989) we expected that 
only a fraction of the hybrids in either series would retain 
the putative inhibitory locus. 
To test the effects of the introduced chromosomes on 
myoD expression, we initially determined whether the 
lOTV2(4n) and lOTV2(8n) hybrids could be converted to 
muscle following treatment with aza-C. Since the endoge- 
nous myoD gene is known to be activated in lOTV2 cells 
treated with aza-C (Davis et al., 1987) and since this activa- 
tion results in conversion of these cells to muscle, failure 
of the hybrids to convert to muscle after aza-C treatment 
would indicate the presence of an inhibitory locus. Cul- 
tures of each hybrid clone were exposed to aza-C for 24 
hr, plated at clonal density, and grown to - 104 cells per 
colony. Myogenic conversion was assayed by immuno- 
staining with a myosin heavy chain antibody, as described 
previously (Thayer and Weintraub, 1990). Four out of five 
clones from the lOTV2(4n) series hybridscould not be con- 
verted to muscle at frequencies similar to control lOTV2 
cells (Figure 1). The relatively low (1%-50/b) but detectable 
myogenic conversion of some chromosome 4 hybrids, such 
as lOTV2(4n)3, 1 OTI/2(4n)-6, 1 OTV2(4n)-8, and 1 OTV2(4n)- 
10, is due to loss of chromosome 4 sequences in asubpop- 
ulation of cells present in each primary hybrid clone (C. 
D. and M. J. T., unpublished data). In contrast, all of the 
1 OTV2(8n) clones convert to the muscle phenotype follow- 
ing treatment with aza-C at frequencies similar to control 
lOTV2 cells (data not shown). These results suggest that 
chromosome 4, but not 8, is involved in inhibiting activation 
of myoD. 
We next determined whether expression of myoD 
mRNA was affected in lOTV2(4n) hybrids that had been 
treated with aza-C. Figure 2 shows Northern blot hybridiza- 
tions of RNA isolated from cultures of lOT% and two 
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Figure 1. Activation of the Muscle Phenotype in the Chromosome 4 
Microcell Hybrids 
Parental and hybrid cell cultures were treated with aza-C for 24 hr, 
plated at clonal density, grown for 14 days, cultured for an additional 
4days in differentiation medium, fixed, and immunostained for myosin 
heavy chain by the alkaline phosphatase method. Colonies were 
scored as positive if they contained darkly staining multinucleated 
myotubes. The values represent the average of two different experi- 
ments with >lOO colonies scored for each cell line. 
1 OTV2(4n) clones treated with aza-C. Consistent with the 
myosin heavy chain immunostaining (Figure l), expres- 
sion of myoD mRNA is detected in lOTV2 and lOTV2(4n)-1 
cells treated with aza-C, but not in lOTV2(4n)-8 cells. In 
addition, treatment of lOTV2 and lOT1/2(4n)-1 cells with 
aza-C results in expression of myosin light chain l/3 (MLC) 
mRNA. Furthermore, consistent with a nonmuscle pheno- 
type and a failure to activate expression of myoD following 
aza-C treatment, 1 OTV2(4n)-8 cells also fail to express high 
levels of MLC mRNA. The low level of MLC gene expres- 
sion seen in these cells is likely due to a minority popula- 
tion of segregant cells, as seen in Figure 1. 1 OT1/2(4n)-3, 
1 OT1/2(4n)-6, and 1 OTV2(4n)-10 also fail to activate myoD 
and MLC mRNAs following treatment with aza-C (data not 
shown). These results suggest that a locus present on 
human chromosome 4 can inhibit activation of mouse 
myoD in lOTV2 cells treated with aza-C. 
Incorporation of aza-C into the DNA of various cell lines 
induces expressioh of a number of genes, including type 
C and intracisternal type A particle (IAP) in lOTY2 cells 
(Hsiao et al., 1986). In addition, activation of IAP RNA in 
1 OTV2 cells treated with aza-C is known to be independent 
of myoD (Davis et al., 1987). Therefore, expression of IAP 
RNA represents a control for activation of gene expression 
induced by aza-C that does not involve myoD. Figure 2 
shows that all three cell lines (lOTV2, lOTV2(4n)-1, and 
lOTV2(4n)8) activate expression of IAP RNA to similar 
levels following treatment with aza-C. These results sug- 
gest that all three cell lines incorporate aza-C with similar 
efficiencies and that the inhibitory effect of chromosome 
4 on myoD expression is specific. 
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Figure 2. Human Fibroblast Chromosome 4 Inhibits Muscle-Specific 
Gene Expression 
Northern blot analysis on 5 pg of cytoplasmic RNA extracted from 
cells treated or not treated with aza-C for 24 hr either once (1X) or 
twice (2X). RNAs were extracted from cells in differentiation medium 
for 4 days. Northern blots were probed with cDNAs corresponding to 
myol), MLC, IAP, or a-tubulin (Tubulin). 
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Inhibition of myoD Transcription 
by Chromosome 4 
To define the mechanism of myoD inhibition by chromo- 
some 4, we assayed myoD transcription in the hybrid cells. 
Enhancer/promoter elements of the human myoD locus 
that direct correct temporal and spatial expression pat- 
terns in transgenic mice have been characterized (Gold- 
hamer et al., 1992). The human my00 gene contains a 
basal promoter region located within the first 2.5 kb up- 
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Figure 3. Human Fibroblast Chromosome 4 Inhibits myoD Enhancer/ 
Promoter Activity in Transient Assay 
(A) The 22 kb Vflanking region of the human myoD locus contains a 
4 kb enhancer and a 2.5 kb promoter (hatched) region that are sepa- 
rated by 19 kb of sequence. An enhancer core element (closed bar) 
is located within the 4 kb fragment. The core enhancer (insertion) is 
255 bp in length and contains four E boxes (El, E2, E3, and E4) and 
two putative Msxl-binding sites (Ml and M2) (Goldhamer et al., 1995). 
(8) F3/-2.5 CAT is a CAT gene linked to the 2.5 kb promoter and the 
4 kb enhancer (Goldhamer et al., 1992). F3AkCAT and -25W2.5 CAT 
are virtually the same as F3/-2.5 except that the myoD promoter is 
replaced by the herpes virus t/r promoter and the 4 kb enhancer by 
the 259 bp core enhancer element, respectively. 
(C) iOT%, lOTVz(4n)l, and lOT%(4n)-9 cells were transfected with 
5 ug of the myoD enhancer/promoter (F3/-2.5 CAT) construct and 5 
pg of pBluescript KS. Cells were harvested after 72 hr. and CATassays 
were performed. 1 OT*h(4n)-9 cells had approximately C-fold lower lev- 
els of CAT activity than 10TH or 1 OTVz(4n)-1 cells. The values repre- 
sent the average of six separate experiments, with each experiment 
containing three dishes per cell line. 
stream of the transcriptional start site and an enhancer 
region of 4.0 kb located approximately 20 kb upstream of 
the promoter (Goldhamer et al., 1992; Figure 3A). Re- 
cently, a 258 bp “core” enhancer element, located within 
the 4.0 kb enhancer, was identified and retains the ability 
to recapitulate the temporal and spatial expression pattern 
in vivo (Goldhamer et al., 1995). We utilized reporter con- 
structs (Figure 38) consisting of either the 4.0 kb enhancer 
region (F3) or the 258 bp core enhancer and 2.5 kb pro- 
moter region fused with the bacterial chloramphenicol ace- 
tyl transferase (CAT) gene. 
The constructs were transfected into 1 OTVz , 1 OT%(4n)-1, 
and lOTV2(4n)-8 cells, and cell extracts were assayed for 
CAT activity. Figure 3C shows that the CAT activity pro- 
duced from the 4.0 kb enhancer/promoter construct in 
iOTV2(4n)-1 was similar to that of lOT% cells, but was 
approximately 5-fold higher than that of 1 OTV2(4n)-8. Simi- 
larly, CAT activities produced by the 258 bp enhancer/ 
promoter construct were significantly higher in lOTV2 and 
lOT1/2(4n)-1 than in lOT1/2(4n)-8(P. W. and M. J.T., unpub- 
lished data). These results suggest that a locus on human 
fibroblast chromosome 4 inhibits myoD transcription. 
Regional Localization of the Inhibitory Locus 
Chromosome fragmentation occurs in microcell hybrids, 
and these fragment-containing hybrids can be used to 
generate physical maps of the fragmented chromosomes 
(Leach et al., 1989). To determine whether the chromo- 
some 4 inhibitory activity could be mapped to a specific 
chromosomal region, we screened the lOT%(4n) series 
hybrids for retention of specific DNA sequences, repre- 
senting genes or unique sequences, known to reside on 
human chromosome 4. Figure 4 shows a schematic repre- 
sentation of human chromosome 4 with the approximate 
Figure 4. Retention of Chromosome4 Markers in the iOT%(4n) Series 
Microcell Hybrids 
Schematic diagram of human chromosome 4 showing the approximate 
map positions of marker loci. Retention of specific chromosome 4 
markers in five different lOT%(4n) series hybrids are indicated. 
iOT%(4n)-3, 10T1/z(4n)-5, and lOT%(4n)-10 retained all markers 
tested. lOT%(4n)-1 retained all markers tested except for the three 
most distal short arm markers D4S412, A&Xl, and 048432. 
lOTl2(4n)-8 retained Only four markers D4S472, MSX7,049432, and 
D‘fs397. 
map positions of the markers tested. Three of the hybrids 
that retain the inhibitory locus (lOT%(4n)-3, lOTV2(4n)-8, 
and 1 OT%(4n)-10) retain all markers tested and were unin- 
formative for regional localization. However, lOT%(4n)-1 
and lOT%(4n)-8 retain fragments of chromosome 4. 
lOTV2(4n)-1, which does not retain the inhibitory locus, 
retains all markers tested except the three most distal 
short arm markers (D&412, A&Xl, and D4S432). In con- 
trast, lOT%(4n)-8, which does retain the inhibitory lo- 
cus, retains only four markers, D4S397 and the three 
most distal short arm markers. Therefore, lOTV2(4n)-1 
and lOTV2(4n)-8 retain a nearly completely nonoverlap- 
ping set of markers, having only D4S397 in common. 
Since lOTV2(4n)-8 retains the myoD inhibitory locus and 
lOTV2(4n)-1 does not, the inhibitory locus must reside in 
the region of nonoverlap between these two hybrids. This 
suggests that the myoD inhibitory locus resides on the 
short arm of chromosome 4 in the region of D4S412, 
A&Xl, and 043432. 
One method for characterizing genes identified by 
purely genetic approaches is to analyze candidate genes 
that map to the same chromosomal position. The chro- 
mosomal location of the human MSX7 gene in the re- 
gion of nonoverlap between the hybrids 1 OT1/2(4n)-1 and 
1 OT%(4n)-8, as well as the observation that forced expres- 
sion of Msxl in musclecells results in adecrease in steady- 
state levels of myoD mRNA (Song et al., 1992) led us 
to examine MSX7 as a candidate for the myoD inhibitory 
locus. 
Expression of Msxl during Early Limb Development 
The pattern of Msxl expression during murine and avian 
development has been extensively described (Hill et al., 
1989; Robert et al., 1989). A correlation of the distribution 
of Msxl transcripts in relation to myogenic cells has not 
been made, although a reciprocal relationship between 
myogenic differentiation and Msxl expression has been 
proposed (Wang and Sassoon, 1995). Mouse forelimbs 
are first recognizable as outgrowths by 9.25-9.5 days 
postcoitum (dpc) (-24 somites), and at this stage, cells 
with myogenic potential can be isolated from limb mesen- 
thyme even though myoD family member gene expres- 
sion is not detectable (Sassoon et al., 1989; Tajbakhsh 
and Buckingham, 1994). To determine whether Msxl is 
expressed in these early stage limb buds, we performed in 
situ hybridizations to 9.25 and 10.5 dpc limb buds. Figure 5 
shows high level Msxl expression in entire limb mesen- 
thyme at 9.25-10.5 dpc. A similar distribution of Msxl 
expression has been reported in facial mesenchyme (Mac- 
kenzie et al., 1991), which contains myogenic precursor 
cells. We conclude that Msxl expression precedes myo- 
genie regulatory gene transcript accumulation during early 
stages of limb development. Within the limits of resolution 
of in situ hybridization, Msxl transcripts are present in all 
mesenchyme of the limb that gives rise to the various tis- 
sue types, including skeletal muscle. Thus, the expression 
pattern of Msxl is consistent with a role as a negative 
regulator of myogenic differentiation at several embryonic 
sites, including the limb. 
Figure 5. Msxl Expression in the Entire Limb Bud Mesenchyme at 
9.25 and 10.5 dpc 
(A)Photomicrographofa9,25dpcmouseembryo( -24somites)show- 
ing the extent of fore limb outgrowth at the time of our experiments. 
The light blue line indicates the level of the transverse section in (B) 
and (C). 
(B) Bright-field photomicrograph of a 5 pm thick section of a 9.25 dpc 
embryo at the level of the fore limb bud. I. limb; s, somite; nt, neural 
tube. This section was hybridized with a cRNA probe corresponding 
to &xl. 
(C) Dark-field photomicrograph of the same section in (B) showing 
intense Msxl signal in the dorsal neural tube and in the entire limb 
bud mesenchyme just distal to the somite region. 
(D) Bright-field photomicrograph of a 5 nm thick section of a 10.5 dpc 
embryo (35 somites) at the level of the fore limb bud. I, limb; s, somite; 
nt, neural tube. This section was hybridized with a cRNA probe corre- 
sponding to Msxl . A comparable mid-limb transverse section to the 
9.25 dpc embryo (A, 8, and C) is shown. 
(E) Dark-field photomicrograph showing intense Msxl labeling in the 
limb bud mesenchyme. 
Expression of MSXl in Primary Human Fibroblasts 
and in lOTM(4n) Hybrids 
One criterion for a candidate inhibitory gene is that it 
should be expressed in the parental human fibroblast 
cells, as well as in hybrids that retain the inhibitory locus, 
but not in lOTI/ cells. We assayed expression of MSXl 
mRNA in lOTV2 and the lOT1/2(4n) microcell hybrids by 
Northern blot hybridization. Cytoplasmic RNAs from 
human skin fibroblast (HSF), lOTV2, lOTV2(4n)-1, and 
lOT1/2(4n)-8 cells were probed with a labeled fragment of 
MSXl Inhibits Expression of MyoD 
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Figure 6. Expression of MSXl in Primary HSFs and in the lOT%(4n) 
Hybrids 
Poly(A)+ RNAs (200 ng) from HSFs (lane l), 1 OTlh (lane 2), 1 OTG(4n)-1 
(lane 3), and lOTl/z(4n)-6 (lane 4) were fractionated on agarose-formal- 
dehyde gels, blotted, and hybridized with radiolabeled MSXl and 
a-tubulin probes. MSXl transcripts were detected in HSF and 
lOTlh(4n)-6, but not in lOTI/ or lOTW(4n>l. 
human MSX7 cDNA. The 150 bp probe detects a -2 kb 
transcript expressed in the human fibroblasts and in 
lOT1/2(4n)-6, but not in lOTI/ or lOT%(4n)-1 (Figure 6). 
In addition, we do not detect expression of mouse Msxl 
mRNA in lOTY2 cells using mouse &xl-specific primers 
and reverse transcription-poiymerase chain reaction (RT- 
PCR) (M. J. T., unpublished data). Thus, expression of 
MSX7 correlates with the presence of the inhibitory locus 
in primary HSFs and in the hybrids that fail to activate 
myoD expression. 
Forced Expression of Msxl Inhibits 
myoD Transcription 
We had previously generated cell lines that stably express 
Msxl using F3 myogenic cells (Song et al., 1992). One 
cell line from this study (F3 1 -c) expresses very high levels 
of Msxl and steady-state levels of myoD7 mRNA are not 
detectable, resulting in lack of differentiation. CAT con- 
structs containing the human myoD enhancer/promoter 
elements (see Figure 38) transiently transfected into F3 
neo (control) and F3 l-c (Msxl-expressing) cell lines show 
that the F3E2.5 CATconstruct produces high CAT activity 
in control ceils, whereas CAT activities are decreased by 
P-fold in F3 l-c cells (Figure 7A). We further performed 
cotransfection experiments using a vector to express 
Msxl (SPHox-7.7)(Songet al., 1992). In F3 neocells, Msxl 
reduces CAT activity greater than B-fold (Figure 7A), 
whereas the control construct, SPHox-7R, which contains 
the Msxl cDNA in the antisense orientation, does not sup- 
press activity. Using a construct containing the myoD en- 
hancer (F3 fragment) fused to the herpes virus thymidine 
kinase promoter (F3/?k CAT), we see a similar repression 
of CAT activity in the cotransfection assay with Msxl , and 
no effect is seen using RSV-CAT as the reporter (Figure 
78). Thus, we conclude that the Msxl effects are specific 
to the myoD enhancer and that the myoD enhancer is a 
target for Msxi-mediated repression. 
Msx2, a closely related member of the msh gene family, 
has a pattern of expression similar to that of Msx7 and 
contains a nearly identical homeodomain (Monaghan et 
al., 1991). To test whether these genes share a common 
molecular function, we tested the effect of forced expres- 
sion of MsxP on the myoD regulatory constructs. We ob- 
serve an inhibitory effect on the human myoD constructs 
by MsxP similar to those observed with Msxl (Figure 7C). 
To determine whether inhibition is specific to themsh gene 
family, or whether inhibition is a common feature among 
all homeoboxcontaining genes, we tested the effects of 
forced expression of Hoxd4 cDNA on the myoD regulatory 
C 
Figure 7. Msxl Represses the Human my00 cis Regulatory Elements 
(A) Two human myoD promoter/enhancer constructs were assayed by transient transfection. Results from four independent experiments are 
presented as relative activities (normalized for transfection efficiency). The CAT activity of the two constructs in F3 neo cells were set as 100%. 
In F3 l-c cells, the activities of the myoD promoter/enhancer of both constructs are reduced P-fold compared with those in the control F3 neo 
cells. When the CAT constructs were cotransfected (into F3 neo cells) with the Msxl expression vector (SPHox-7.1) (lane Msxl) at I:1 ratio, the 
CAT activities of both constructs are reduced by more than &fold. Vector carrying Msxl cDNA in an antisense orientation (SpHox-7R) (lane MsxlR) 
does not repress CAT activity of these constructs. 
(8) Reporter constructs carrying heterologous promoter, F3/t/r CAT (lane F3/tkCAT, Msxl), and viral promoter/enhancer, RSV-CAT (lane RSVCAT, 
&xl), were also tested independently against Msxl-expressing construct. The basal levels of the constructs in F3 neo cells were set as 100%. 
(C) Different effector constructs expressing Msxl, &x2, and Hoxd4, respectively, were tested in cotransfection experiments by using the reporter 
construct, F3/-2.5 CAT. The activity of the F3/-2.5 CAT is set as 100% in F3 neo cells (lane F3/-2.5 CAT). 
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constructs. As shown in Figure 7C, the Hoxd4 construct 
has only a small affect on the myoD enhancer activity in 
the cotransfection assay, suggesting that repression of 
the myoD enhancer is not a common feature among all 
homeodomain proteins. 
Msxl Binds to the Human myoD Enhancer 
We next determined whether repression of the myoD en- 
hancer could be mediated by direct binding of the Msxl 
protein to the myoD enhancer by using a DNA mobility 
shift assay. Msxl protein was synthesized in vitro, and 
SDS-polyacrylamide gel electrophoresis analysis reveals 
a major translation product with an apparent molecular 
weight of 32 kDa, corresponding to the size of predicted 
protein for Msxl (Figure8A). Two additional bandsof lower 
molecular weight are detected at lower abundance, which 
likely result from premature termination during the transla- 
tion or proteolytic degradation. A %P end-labeled probe 
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Figure 6. Msxl Protein Binds Directly to the myoD Enhancer 
(A) Msxl proteins were synthesized in vitro by using rabbit reticulocyte 
lysate system. [36S]methionine-labeled Msxl protein was detected by 
autoradiography. The major band (arrow) represents the full-length 
Msxl protein as predicted from the cDNA sequence of Msxl. Two 
bands of less intensity, likely resulting from premature termination 
during translation or protaolytic degradation of the full-length protein 
product, were also detected. Lysate containing no Msxl RNA does 
not produce radiolabeled protein products. 
(6) Binding of Msxl to the myoD enhancer was detected by a gel 
mobility shift assay at different salt concentrations (left lanes: 10 mM 
Tris (pH 7.5), 50 mM NaCI, 1.5 mM MgCI,, 1 mM DlT, and 5% glycerol; 
right lanes: the concentration of each component is half those used 
in the lefl lanes). The KCI concentration of all the lanes is 50 mM. A 
discrete band (arrow) is seen in the lanes that Msxl proteins were 
present. A lower band is also observed, which may represent binding 
by shorter translation products or by more than one Msxl proteins. 
The probe was an end-labeled PCR product spanning the first 129 
base pairs of the myoD core enhancer element. 
was prepared from a PC&generated fragment, corre- 
sponding to a 129 bp fragment from the 5’ end of the 258 
bp myoD enhancer. Lysate with no Msxl mRNA was used 
as a negative control. At least two specific bands are ob- 
served in the presence of Msxl protein (Figure 8B). The 
different bands may be due to binding of different size 
proteins, as is shown in the translation products (Figure 
8A), or to binding of a number of Msxl proteins to multiple 
Msxl-binding sites in the probe (see Figure 3A). These 
results suggest that repression of the myoD enhancer by 
Msxl is mediated by binding of Msxl to the myoD en- 
hancer. 
Antisense MSX7 Relieves Repression 
of myoD Transcription 
To determine whether MSX7 is responsible for inhibition 
of myoD activation, we tested whether expression of anti- 
sense MSXl could relieve repression of myoD transcrip- 
tion in the chromosome 4 hybrids. A genomic MSX7 frag- 
ment containing the first exon and - 1.0 kb 5’ to the 
transcriptional start site was cloned in the antisense orien- 
tation in the expression vector pEMSV (Davis et al., 1987). 
This construct was cotransfected with the F3l-2.5 myoD 
enhancer/promoter CAT construct into 1 OTM , 1 OT%(4n)-1, 
and lOT1/2(4n)-8 cells. Control constructs included the 
same MSXl genomic fragment cloned into pEMSV in the 
sense orientation and the empty parental vector pEMSV. 
The sense MSXl construct is not expected to have biologi- 
cal activity, since it does not contain the entire second 
exon, which contains the homeodomain (Hewitt et al., 
1991). Consistent with our previous results, lOTR(4n)-8 
contains 5-fold less myoD en hancerlpromoter activity than 
control cells (Figure 9). Significantly, repression of the 
myoD reporter construct in lOT%(4n)-8 is relieved when 
cotransfected with the MSX7 antisense construct, but not 
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Figure 9. Expression of Antisense MSXl Relieves Repression of 
myoD 
lOT%, lOTYz(4n)-1, and lOTr/2(4n)-S cells were transfected with 5 pg 
of the myoD promoter/enhancer CAT plasmid F3/2.5 and 5 ug of either 
sense or antisense MSXl expression plasmid, or pBluescipt KS and 
pEMSV control plasmids. After 72 hr. CAT assays were performed. 
The approximately 5fold lower my00 enhancer/promoter activity ob- 
served in lOTlh(rln)-6 compared with either lOTYz(4n)-1 or parental 
lOT% cells is increased to control levels in the presence of antisense 
MSXl expression plasmid. This graph represents the results of three 
separate experiments, with each experiment containing three dishes 
per data point. 
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with the h&Xl sense or pEMSV constructs. Cotransfec- 
tion of the MSXl expression constructs, either sense or 
antisense, or the pEMSV vector have no affect on the 
activity of the myoD reporter gene in 1 OT1/2 or lOT1/2(4n)-1 
cells. Furthermore, antisense MSXl has no affect on ex- 
pression of the control SV40 enhancer/promoter CAT con- 
struct in either lOT%, lOT1/2(4n)-1, or lOTI/2(4n)8 cells 
(data not shown). These results indicate that expression 
of antisense MSXl can relieve repression of myoD tran- 
scription mediated by human chromosome 4. We con- 
clude that h&Xl represents the myoD inhibitory locus 
present on human chromosome 4, and it functions by in- 
hibiting myoD transcription. 
Discussion 
We have shown that human fibroblast chromosome 4 is 
sufficient to inhibit activation of myoD in lOT% cells. This 
inhibition is mediated through an enhancer located up- 
stream of the myoD gene. The mechanism of inhibition is 
down-regulation of transcription, since hybrids that con- 
tain chromosome 4, as well as cells transfected with an 
Msxl expression vector, contain significantly less myoD 
enhancer activity than lOTI/ cells. Furthermore, analysis 
of chromosome 4 fragment-containing hybrids indicates 
that the inhibitory locus is localized to the short arm of 
chromosome 4, which contains human MSXl. Human 
MSX7 is expressed in the parental primary HSFs, as well 
as in the lOTI/ hybrids that retain the human MSX7 gene. 
Cotransfection of an MSX7 antisense expression vector 
relieves repression and results in levels of myoD enhancer 
activity equal to that found in lOTI/ cells. Therefore, we 
conclude that human MSX7 inhibits myoD transcription in 
primary fibroblast x lOTI/ cell hybrids. 
Negative Regulation of myoD 
Transfer of human chromosome 11 from primary fibro- 
blasts into lOTY2 cells activates human myoD expression 
(Thayer and Weintraub, 1990). Subsequent experiments 
demonstrated that the human myoD enhancer and pro- 
moter are functional in lOTI/ cells and that they direct 
lineage-specific expression in transgenic mice (Gold- 
hamer et al., 1992). These observations suggest that the 
human myoD gene is properly regulated in murine cells 
and that activation of the human myoD gene in lOTY2 
cells is not due to improper regulation between species. 
Although there are several possibilities that could explain 
why 1 OT1/2 cells normally do not express their own myoD 
genes, the data are most consistent with the possibility 
that myoD expression is repressed in cis, probably by 
methylation (Thayer and Weintraub, 1990). Consistent 
with this notion is the observation that the myoD gene 
is methylated in lOTI/ cells and becomes demethylated 
following treatment with aza-C (Jones et al., 1990). The 
myoD CpG island is highly methylated in immortal cell 
lines, but is undermethylated in fetal and adult nonmuscle 
mouse tissues, and becomes methylated when primary 
mouse fibroblasts are grown in culture (Jones et al., 1990). 
Furthermore, transfection of cloned, and therefore un- 
methylated, mouse myoD genomic fragments converts 
lOTI/ cells to muscle (Tapscott et al., 1992). Implicit in 
this argument is that lOTI/ cells lack the myoD inhibitory 
activity present in primary fibroblasts. In our model, re- 
moval of cis repression by aza-C-induced demethylation 
would allow low level myoD transcription that is subse- 
quently enhanced by the positive autoregulatory loop 
(Thayer et al., 1989). Thus, MSX7 can inhibit this low level 
of activity and, therefore, can keep myoD silent. 
MSX7 Inhibits Expression of myoD in Fibroblast x 
10TM Cell Hybrids 
Several observations led us to consider MSX7 as a candi- 
date for the myoD inhibitory locus. First, forced expression 
of murine Msxl in muscle cells results in a dramatic de- 
crease in steady-state levels of myoD mRNA (Song et al., 
1992). Second, the human MSXl gene and the myoD in- 
hibitory locus map to the short arm of chromosome 4. 
Third, fragment-containing hybrids that retain the MSX7 
gene contain the myoD inhibitory activity, while hybrids 
that have deleted the MSXl gene do not. Fourth, human 
MSX7 is expressed in primary HSFs and in the chromo- 
some 4 hybrids, while lOTI/ cells do not express endoge- 
nous Msxl . Fifth, forced expression of Msxl and the chro- 
mosome 4 hybrids repress myoD transcription through the 
same 258 bp fragment of the myoD enhancer. However, 
identification of MSXl as the myoD inhibitory locus was 
established by showing relief of repression of the myoD 
enhancer by antisense MSXl. Furthermore, Msxl binds 
to the myoD enhancer and likely functions as a repressor 
to turn off transcription of myoD. Recently, Msxl has been 
shown to inhibit transcription of the SV40 enhancer/pro- 
moter in the absence of homeodomain DNA-binding sites 
(Catron et al., 1995). This repression presumably occurs 
through protein-protein interactions. Although we observe 
Msxl binding to the myoD enhancer and repression ap- 
pears to be mediated through this enhancer, we do not 
know whether these binding sites are required for repres- 
sion by Msxl. We note that we do not see an affect of 
MSX7 on the SV40 enhancer/promoter construct in our 
chromosome 4 hybrids. This could be explained by a differ- 
ence in the level of Msxl protein achieved by transient 
expression versus cell hybridization. Perhaps DNA-binding 
sites are not required for repression when high levels of 
protein are produced in the cotransfection assay. The sys- 
tem described here should allow us to determine whether 
the Msxl-binding sites present in the myoD enhancer are 
required for repression, or whether Msxl is targeted to 
the myoD enhancer through protein-protein interactions. 
Function of MSXl In Vivo 
Msxl is not expressed in all myogenic progenitor cells, 
such as in the somites (Hill et al., 1989; Robert et al., 
1989). Compelling evidence suggests that myogenic pre- 
cursors in the somites and those in the limb and other 
lateral structures represent different lineages and are reg- 
ulated differently (Ordahl and Le Douarin, 1992). These 
two myogenic programs differ in several important ways, 
including myocyte differentiation (Keynes and Stern, 
1988) sensitivity to axial structures (Teillet and Le Dou- 
arin, 1983; Rong et al., 1992) and phenotypes resulting 
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from mutationofmyoDfamilymembers(Hastyet al., 1993; 
Nabeshima et al., 1993). In addition, Myf5 is expressed 
in myogenic cells in the dermamyotome prior to myotome 
formation, while none of the myoD family members are 
detected until 2 days later in the limbs (Sassoon et al., 
1989; Ott et al., 1991; Tajbakhsh and Buckingham, 1994). 
The cis regulatory elements have been implicated in the 
differential expression of the myoD family members. For 
example, mutation in a conserved E box in the myogenin 
promoter reduces expression in the limb buds and visceral 
arches, but has little effect on expression in somites 
(Cheng et al., 1993). Taken together, the differential ex- 
pression of the myoDfamily members may reflect different 
regulatory factors present in limbs versus somites. 
Several experiments implicate Msxl as a negative regu- 
lator of muscle development. Msxl is expressed in the 
entire limb bud (this study), which contains proliferative 
and undifferentiated cells including determined myoblasts 
when limb outgrowth just begins (Hill et al., 1989; Robert 
et al., 1989). No transcripts for myoD family members are 
detected at this stage (Sassoon et al., 1989; Tajbakhsh 
and Buckingham, 1994). Although our data indicate that 
Msxl is expressed in the entire limb bud at early stages 
and the simplest interpretation is that Msxl is expressed 
in all cells of the limb bud, without single cell resolution 
it remains possible that Msxl expression is excluded from 
myogenic precursor cells. Regardless, at later stages of 
limb outgrowth, Msxl expression and muscle differentia- 
tion are mutually exclusive (Wang et al., 1992). In addition, 
dissociation of limb buds from 9.5 day mice results in pre- 
cocious myoD expression and muscle differentiation ac- 
companied by a rapid decline in Msxl expression (Wang 
and Sassoon, 1995). In this study, we see that Msxl re- 
presses myoD gene expression at the transcriptional level 
leading to the conclusion that the myoD gene is a target 
for a homeobox gene in the muscle lineage and that Msxl 
represents an important factor that negatively regulates 
cellular differentiation by repressing myoD. Recent stud- 
ies suggest that another homeoboxcontaining gene, 
Pax3, is intimately involved in the process of myoblast 
migration from the somite to the limb. In situ analysis re- 
veals a ‘pathway” of labeled cells that precedes myoD 
family member transcript accumulation in the limb (Wil- 
liams and Ordahl, 1994), and Pax3 mutant mice do not 
possess limb musculature (Bober et al., 1994). Thus, ho- 
meobox repression of the myogenic differentiation pro- 
gram may be a general mechanism during patterning of 
early myogenic precursors. 
Given our observations that the adipogenic phenotype 
is also inhibited by chromosome 4 (C. D. and M. J. T., 
unpublished data), it seems likely that Msxl regulates dif- 
ferentiation of other lineages as well. It will be of interest 
to determine whether Msxl regulates genes involved in 
the determination of these other lineages. On6 caveat to 
this interpretation is the observation that Msxl-deficient 
mice do not exhibit an obvious limb phenotype, although 
craniofacial development is severely affected (Satokata 
and Maas, 1994). Owing to the close sequence homology 
and similar expression pattern in the limb, as well as the 
negative effects on myoD transcription shown here, it 
seems likely that Msx2 may substitute for Msxl. In addi- 
tion, MSX2 involvement in limb development is also sug- 
gested by the finding of limb anomalies in patients with a 
mutation in the MSX2 gene causing Boston-type craniosy- 
nostosis (Jabs et al., 1993). It should be possible to test 
the redundancy hypothesis by constructing mice deficient 
for both Msxl and Msx2. It should also be possible to test 
this hypothesis in the hybrid system described here by 
introducing human chromosome 5, which contains MSX2, 
into 1OTVz cells and testing for inhibition of myoD acti- 
vation. 
Experimental Procedures 
CdlS 
C3H1OTYz clone 6 was from the American Type Culture Collection. All 
cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 15% calf serum (Hyclone Laboratories). Cell cul- 
tures were exposed to 3 HIM aza-C for 24 hr either one or two times 
and plated at clone1 density. Myogenic differentiation was induced by 
growing cells to confluence followed by incubation in DMEM with 2% 
horse serum (differentiation medium). 
Mlcrocell-Medlated Chromosome Transfer 
HA(4)-A (mouse A9 cells containing a neo-marked human fibroblast 
chromosome 4) or HA(S)-A (mouse A9 cells containing a net-marked 
human fibroblast chromosome 6) cells were micronucleated by adding 
0.06 pg of colcemid (Sigma) per milliliter in DMEM plus 10% calf serum 
for 49 hr. The micronucleate cell populations were enucleated by cen- 
trifugation in the presence of 5 Kg of cytochalasin B (Sigma) per millili- 
ter, and the isolated microcells were fused to IOTlh recipients as de- 
scribed (Lug0 et al., 1987). Microcell hybrid clones were picked after 
3-4 weeks of selection in medium containing 500 pg of Geneticin 
(GIBCO) per milliliter. 
Northern Blot Analysis 
Total cytoplasmic RNA was prepared as described (Favaloro et al., 
1960). Either 5 pg of total cytoplasmic RNA or - 200 ng poly(A) RNA 
was used for Northern blot analysis on 1.2% agarose gels containing 
6.7% formaldehyde. RNA was transferred to GeneScreen (DuPont) 
by capillary transfer in 10x SSC (1 x SSC is 150 mM NaCI, 15 mM 
Nacitrate). RNA was cross-linked by exposure to UV light, followed 
by baking at 60°C for 2-4 hr. Blots were prehybridized for several 
hours at 42OC in hybridization buffer (50% formamide, 1% bovine 
serum albumin [fraction V], 1 mM EDTA. 0.5 M sodium phosphate 
[pH 7.21, 5% sodium dodecyl sulfate [SDS]). Hybridizations were for 
24 hr at 42OC in fresh hybridization buffer containing 1 x 1Q cpm of 
randomly primed “P-labeled DNA probe. The filters were washed in 
2x SSC, 0.1% SDS for 15 min at room temperature, in 0.1 x SSC, 
0.1% SDS for 15 min at room temperature, and in two changes of 
0.1 x SSC, 0.1% SDS at 55OC for 15 min each. The blots were striped 
for reuse by boiling for 2 min in double-distilled water. The MSXl probe 
was generated by PCR of cDNA, the primers were TCAAGCTGCCA- 
GAAGATGCGCTC and TACGGlTCGTGlTGTGlTTGCGGAG and 
span the first intron (Hewitt et al., 1991). 
In Sltu Hybrldizatlon 
Mouse embryonic tissue was obtained from crosses of BALBlc and 
C3H strains (Charles River). Matings were confirmed by the presence 
of a vaginal plug, and the morning following matings was counted as 
0.5 dpc. At 9.25 and 10.5 dpc, females were sacrificed and embryos 
were dissected free of the decidua and somites were counted under 
a dissection microscope (Wild M3Z) using polarized optics. Tissue was 
fixed and processed for paraffin microscopy and in situ hybridization 
using techniques previously described in detail elsewhere (Sassoon 
and Rosenthal, 1993). A probe corresponding to Msxl was prepared 
as described elsewhere (Robert et al., 1969; Wang et al., 1992). The 
mice used for this study were also part of a study to confirm that 
these limbs do not express myoD nor myogenin as detected by in 
situ hybridization (Sassoon et al., 1989) or by RT-PCR (Wang and 
Sassoon, 1995). 
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PCR Analysis 
High molecular weight DNA (100 ng) was subjected to PCR in the 
presence of 67 mM Tris @H 6.8), 16 mM (NH&& 10 mM Bmer- 
captoethanol, 6.7 PM EDTA, 2.0 mM MgCI,, 10% glycerol, 0.2 mM 
dNTPs, 0.2 pM primers, 1.3 U of Taq polymerase (Cetus). Following 
a 4 min soak at 96OC, samples were amplified 35 cycles: 30 s at 94“C, 
30 s at 55OC, 30 s at 72OC. Samples were electrophoresed on 3.5% 
acrylamide gels and stained with ethidium bromide. Primers were 
045412, 04S432, 04S404, D4S409, D4S421, D4S397, D4S413, 
D4S426 (Research Genetics), QDPR, AFP (Theune et al., 1991), and 
MSXl AATCCCGTAGGAGCGAAGTGTTC and CTCGATGTCCACAT- 
ClTAGGCCT (Hewitt et al., 1991). 
Cell Transfectlons 
Cells were transiently transfected by either the calcium phosphate 
(CaPOI) (Chen and Okayama, 1987) or lipid (Felgner et al., 1987) 
methods. Approximately 3 x 105 cells were plated 1 day prior to trans- 
fection into 80 mm tissue culture plates. The day of transfection, the 
cells were refed with DMEM plus 15% serum (CaPO,) or DMEM alone 
(lipid). Several hours later, cells were transfected with 10 pg of DNA 
per plate comprised of 1 pmol of various CAT reporter plasmids and 
2-9 pg of other constructs as shown in the text. The CaPO, precipitate 
remained on the cells for 24 hr. while the lipid-DNA mixture remained 
on for 3 hr, after which DMEM plus 15% serum was added. The follow- 
ing day, the cells were refed with DMEM plus 15% serum and har- 
vested 24 hr later. 
CAT Assays 
CAT activity was measured using a phase extraction procedure (Seed 
and Sheen, 1988). In brief, 48 hr after transfection. cell extracts were 
made by freeze-thawing cell pellets in 60 ul of 0.25 M Tris (pH 8.0). 
Following treatment at 65OC for 15 min to inactivate endogenous ace- 
tylases, 30 pl of extract was assayed with 0.2 mCi of [3H]chlorampheni- 
col (Dupont-New England Nuclear) and 250 mM butyryl-CoA (Sigma), 
in a total volume of 100 pl. The reaction was allowed to proceed from 
2-18 hr at 37“C and then stopped by mixing with 200 ~1 of TMPD- 
Xylene (2:l) (Sigma), and then 180 pl of the top layer was added to 
2 ml of scintillation cocktail and counted. CAT activity was normalized 
to counts from cells transfected with the control vector pCAT enhancer 
(Promega). Results are presented in percentage activity with error 
bars indicating standard deviation. 
In Vitro Translation and Electrophoretlc Moblllty Shift Assay 
In vitro translation was performed by using rabbit reticulocyte lysate 
system (Promega) in a50 PI mixture containing 1 .O pgof in vitrosynthe- 
sized t&xl RNA, 33 pl of reticulocyte lysate, supplement amino acids 
(1 mM each), 70 mM KCI, 10 pCi of [“Slmethionine (Dupont-New 
England Nuclear), 2.4 mM MgC&. and 0.5 U/VI RNasin (Promega) at 
30°C for 60 min. The “S-labeled proteins were resolved on a 5% 
SDS-polyactylamide gel. Prestained molecular weight markers were 
used to determine the size of labeled proteins. 
For each gel shift assay, 2.2 PI of lysate containing translation prod- 
ucts was incubated with a gel-purified end-labeled probe (105 CPM) 
in a total volume of 20 pl containing 10 mM Tris (pH 7.5), 50 mM NaCI, 
2.5 mM MgCl*, 1 mM DTT, 1.5 ag of poly(dl-dC), and 25-50 mM KCI 
at room temperature for 15 min. Samples then were resolved on a 
5% nondenaturing polyacrylamide gels in 0.4 x TAE (16 mM Tris, 8 
mM acetic acid and 0.4 mM EDTA (pH 7.9). Autoradiography was 
performed with intensifying screen for 14-36 hr at -8OOC. The DNA 
probe was a PCR product spanning the first 129 bp of the human 
myoD enhancer core element. 
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